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Abstract Anti-angiogenesis targeting VEGFR-2 has been
considered as an important strategy for cancer therapy.
Ellagic acid is a naturally existing polyphenol widely found
in fruits and vegetables. It was reported that ellagic acid
interfered with some angiogenesis-dependent pathologies.
Yet the mechanisms involved were not fully understood.
Thus, we analyzed its anti-angiogenesis effects and
mechanisms on human breast cancer utilizing in-vitro and
in-vivo methodologies. The in-silico analysis was also
carried out to further analyze the structure-based interac-
tion between ellagic acid and VEGFR-2. We found that
ellagic acid significantly inhibited a series of VEGF-
induced angiogenesis processes including proliferation,
migration, and tube formation of endothelial cells. Besides,
it directly inhibited VEGFR-2 tyrosine kinase activity and
its downstream signaling pathways including MAPK and
PI3K/Akt in endothelial cells. Ellagic acid also obviously
inhibited neo-vessel formation in chick chorioallantoic
membrane and sprouts formation of chicken aorta. Breast
cancer xenografts study also revealed that ellagic acid
significantly inhibited MDA-MB-231 cancer growth and
P-VEGFR2 expression. Molecular docking simulation
indicated that ellagic acid could form hydrogen bonds and
aromatic interactions within the ATP-binding region of the
VEGFR-2 kinase unit. Taken together, ellagic acid could
exert anti-angiogenesis effects via VEGFR-2 signaling
pathway in breast cancer.
Keywords Ellagic acid  Anti-angiogenesis 
VEGF/VEGFR2  Molecular docking  Breast cancer
Introduction
In recent decades, breast cancer has attracted global con-
cern in recent decades. The global burden of breast cancer
has engineered oncologists to develop novel strategies for
breast cancer prevention and treatment [1, 2]. It has been
recognized that angiogenesis is one of the essential hall-
marks of cancer, typically breast cancer. To sustain growth,
tumors require sufficient nutrients, oxygen, and certain
effective ways to evacuate waste. All the aforementioned
needs can be addressed by angiogenesis, the process that
consistently forms novel blood vessels into tumor masses
from existing endothelium-lined vessels. Besides, exten-
sive laboratory evidences supported that tumoral angio-
genesis can be detected throughout the onset, growth, and
metastasis in breast cancer [3, 4]. Thus, the anti-angio-
genesis therapy has become one of the most important
modalities in breast cancer treatment.
Angiogenesis process is orchestrated by a balance
between pro- and anti-angiogenic factors. During breast
cancer progression, angiogenesis occurs when the activity
of stimulators exceeds that of inhibitors. After vessel
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invasion into breast tumor masses, there are at least six
different angiogenesis-associated growth factors secreted,
among which vascular endothelial growth factor (VEGF) is
the most potent angiogenesis stimulator [5, 6]. The specific
action of the VEGF on the endothelial cells is mainly
mediated by two types of receptor tyrosine kinases (RTKs),
namely VEGFR-1 (Flt-1) and VEGFR-2 (KDR in human/
Flk-1 in mice) with high affinities. Of the two receptors,
VEGFR-2 plays a more important role in mediating the
mitogenesis and permeability of endothelial cells. Activa-
tion of VEGFR-2 contributes to phosphorylation of mul-
tiple downstream signals including ERK, JNK, and AKT
that subsequently promote proliferation, migration, and
tube formation of endothelial cells. Considering anti-
angiogenesis therapy is to target endothelial cells that
support tumor growth rather than cancer cells themselves,
VEGFR-2 has become an important therapeutic target for
cancer anti-angiogenesis therapy [7–10].
VEGFR-2 belongs to the most aggressive RTKs. Agents
now targeting RTKs in oncology can be roughly divided
into three categories—antibodies targeting RTK ligands
(i.e., targeting VEGF), antibodies targeting receptors
themselves (i.e., targeting VEGFR-2), and small molecular
inhibitors targeting VEGFR-2 kinase domain [11]. The
recombinant of the three-dimensional crystal structure of
VEGFR-2 kinase domain provided a basis for structure-
based design of small molecular inhibitors. Structurally,
VEGFR-2 consists of 1,356 amino acids in humans, and
can be separated into three domains: the extracellular
VEGF-binding domain consisting of seven immunoglobu-
lin-like segments, the transmembrane domain, and the
intracellular catalytic domain possessing tyrosine kinase
activity. Upon specifically binding to VEGF, VEGFR-2
would undergo dimerization within the extracellular
domain and autophosphorylation within the intracellular
catalytic domain by consuming ATP, accompanied by
following activation of downstream signaling cascades that
stimulate angiogenesis. The ATP-binding site and less
conserved surrounding sites are thus especially important
for anti-VEGFR2 agent design [12, 13].
Various orally active small molecular inhibitors of
VEGFR-2 are now in clinical trials including sunitinib,
vandetanib, and sorafenib [14]. Disappointedly, long-
duration treatment with these agents might be accompanied
by distinct adverse effects such as hemorrhage, hyperten-
sive crisis, and gastrointestinal perforation [15]. Therefore,
there has been renewed interest in natural inhibitors that
could block VEGFR activation. Many natural phenolic
compounds or their specific derivatives are found pos-
sessing potent anti-cancer properties [16–18]. Among
them, ellagic acid (4,40,5,506, 60-hexahydroxydiphenic acid
2,6,2060-dilactone) is a representative small molecular pol-
yphenol widely found in fruits and vegetables. Extensive
studies have reported that ellagic acid exerts potent anti-
oxidant effects either by directly acting as an antioxidant or
by activating cellular antioxidant enzyme systems [19, 20].
In addition, ellagic acid was also found to be effective in
anti-carcinogenesis through inhibiting tumor cell prolifer-
ation, inducing apoptosis, breaking DNA binding to car-
cinogens, and most importantly, disturbing angiogenesis
processes required for tumor growth [21]. However, the
mechanisms involved were not thoroughly elucidated.
In this study, the effects of ellagic acid on inhibiting
breast cancer angiogenesis were validated in vitro and in
vivo. Mechanistic study further indicated that ellagic acid
could significantly inhibit VEGFR-2 kinase activity and
block its signaling pathway both in vitro and in vivo.
Meanwhile, the structure-based interaction between ellagic
acid and VEGFR-2 was found to be stable conformation
based on in-silico analysis which revealed that hydrogen
bond and aromatic interactions were formed.
Materials and methods
Cell culture and drug preparation
The human breast cancer cell line MDA-MB-231 was
purchased from the American Type Culture Collection
(ATCC), and maintained in L-15 medium supplemented
with 10% FBS, penicillin (100 U/ml), and streptomycin
(100 lg/ml). Human umbilical vein endothelial cells
(HUVEC) were cultivated in gelatinized culture plates in
M199 medium supplemented with 15% FBS, 1% PS,
50 lg/ml endothelial cell growth supplement (ECGS, BD
Bioscience) and 100 lg/ml heparin at 37C in a humidified
atmosphere containing 5% CO2. Ellagic acid (C98%,
Sigma-Aldrich, St. Louis, MO) was dissolved in dimethyl
sulfoxide (DMSO, final concentration is 0.1%) was diluted
in 19 PBS to prepare required concentrations. In each
treatment, the cells were treated with vehicle or with
various concentrations of ellagic acid in the presence of
20 ng/ml human VEGF (Pepro Tech, Rocky Hill, NJ).
Cell counting assay
HUVECs were seeded in a 6-well plate with a density of
2 9 104 cells per well at 37C and 5% CO2 for overnight
attachment. Then the cultivated medium was discarded and
replaced with fresh serum-free medium with or without
drug involvement in the presence of VEGF. At the time
intervals of 12, 24, and 48 h, cells were harvested for
counting in the presence of trypan blue. All samples were
assayed in triplicate to generate proliferation curves as
described.
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BrdU incorporation assay
DNA synthesis was determined by BrdU labeling assay
using Cell Proliferation ELISA, BrdU (colorimetric) kit. In
brief, 3,000 HUVECs per well were seeded in a gelatin-
coated for overnight attachment. Then the cultivated
medium was replaced with serum-free medium supple-
mented with 20 ng/ml VEGF as well as different concen-
trations of ellagic acid in a final volume of 100 ll/well.
After 24 h, cells were labeled with BrdU (2 h, 37C),
incubated with FixDenat solution (30 min, 20C), and re-
incubated with Anti-BrdU POD (90 min, 20C). The
sample absorbance was finally detected in an ELISA reader
at 450 nm.
Lactate dehydrogenase (LDH) toxicity assay
The LDH released into cell cultures is an index of cyto-
toxicity and evaluation of the permeability of cell mem-
brane. HUVEC were seeded in 96-well plate at a density of
3,000 cells per well. After incubation with various con-
centrations of ellagic acid for 24 h, cell supernatants were
collected and analyzed for LDH activity using LDH cyto-
toxicity assay kit from Caymen Company. The absorbance
of formed formazan was read at 490 nm on a microplate
reader.
Wound-healing assay
HUVEC cells were seeded in a 6-well plate at a density of
5 9 105/well. After the cells had reached 90% confluency,
a scrape was made in the middle of the plate by a 10 ll tip
with the gap widths between 150 and 200 lm. After
scrapping, the cells were washed with PBS twice, and then
incubated with fresh medium containing VEGF with or
without ellagic acid (10 lM). Migration ability was eval-
uated by measuring the gap widths narrowed down by
HUVECs movement at different time intervals of 0, 12,
and 24 h. Images were then taken with a microscope video
system, and three places of each gap were measured and
averaged.
Invasive assay
Transwell model (8-lm pore size) was applied to perform
the invasive assay. The upper side of transwell was coated
with Matrigel, while the lower compartment was coated
with type I Collagen. Then the pre-coated transwell was
placed into a well of 6-well plate containing 1 ml complete
M199 medium. HUVECs (2 9 105 cells per well) were
suspended in 1 ml medium containing various concentra-
tions of ellagic acid and VEGF, and then added to the
upper chamber. After incubation at 37C for 24 h, the non-
migrated cells in the upper surface of membrane were
removed with a PBS-soaked cotton swab. Then the mem-
branes were fixed with 4% PFA for 30 min. Cells that
migrated to the lower side of the membranes were stained
with HE method. Photographs were taken by a microscope
video system. The number of cells that crossed the mem-
brane in the treated group was compared with that in the
control group.
Tube formation assay
The tube formation assay was performed using 12-well
plate coated with 100 ll Matrigel basement membrane
matrix (BD Bioscience, Bedford, MA) per well and poly-
merized at 37 for 30 min. HUVECs suspended in M199
medium containing 2% FBS were plated on the Matrigel at
a density of 2 9 105 cells/well. Different concentrations of
ellagic acid (2.5, 5, and 10 lM) were then added together
with VEGF (20 ng/ml). After 8 h, The Matrigel-induced
morphological changes of HUVECs and their formed tube
networks were observed under a microscope and photo-
graphed at a five-fold magnification.
Kinase activity detection
In vitro VEGFR-2 tyrosine kinase activity was assayed
using an enzyme-linked immunosorbent assay kit (Boeh-
ringer Mannheim, SA). In brief, ellagic acid was incubated
with VEGFR-2 (Upstate) in assay buffer containing Mg2?
and ATP in 96-well plate coated with a poly-Glu-Tyr
substrate. Phosphorylated tyrosine was then detected by
sequential incubation with a mouse IgG anti-phosphoty-
rosine antibody and an HRP-linked sheep anti-mouse
immunoglobulin antibody. Color was developed with an
HRP chromogenic substrate and quantified by an ELISA
reader at wavelength 450 nm. The results were expressed
as percent kinase activity.
Western blotting
In brief, cell lysates (30 lg) were separated by 8% SDS-
PAGE and transferred to polyvinylidene difluoride mem-
branes. Membranes were then incubated with primary
antibodies including phosphorylated and/or total VEGFR-
2, ERK, AKT, JNK, eNOS, and b-actin (Cell Signaling
Technology, Danvers, MA). After overnight incubation at
4C, membranes were washed with TBST three times and
then incubated with secondary antibodies at room tem-
perature for 2 h. Immunoreactive bands were then visual-
ized by the enhanced chemiluminescence (ECL) detection
system (GE healthcare).
Breast Cancer Res Treat
123
Gelatin zymography
Supernatants from a HUVEC culture system with or
without ellagic acid treatment were collected for MMPs
activity analysis by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis under non-reducing conditions. One
milligram per milliliter of gelatin was prepolymerized on a
10% polyacrylamide gel as a substrate. Electrophoresis was
carried out at 4C. The gel was washed with washing buffer
(50 mM Tris–HCl, pH 7.5, 100 mM NaCl, and 2.5% Triton
X-100), followed by incubation with a buffer (50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.02%
NaN3, and 1 lM ZnCl2) at 37C for 16 h and visualized
with Coomassie Blue R-250.
Measurement of reactive oxygen species
2070-Dichlorofluorescein diacetate (DCFH-DA, Sigma, St.
Louis, MO) was used to measure ROS formation. After
exposed to different concentrations of ellagic acid for 24 h,
endothelial cells were then incubated in DCFH-DA con-
taining medium (final concentration: 10 lM) at 37C for
20 min. Cells were washed with PBS three times to remove
DCFH-DA that not entered in cells. The fluorescence was
visualized immediately at wave lengths of 485 nm for
excitation and 530 nm for emission by inverted fluores-
cence microscope. Total green fluorescence intensities of
each well were quantified using image analysis software.
Chick aortic ring models
In brief, the aortic arches were dissected from 12-day-old
chick embryos, cut into rings and embedded into Matrigel
in a 6-well plant. After overnight incubation at 37C, rings
were added with serum-free medium containing ellagic
acid in the presence of VEGF. Sprouts were formed within
48–72 h. Images were photographed at 59 magnification
of a Zeiss inverted microscope. The extent of sprouts for-
mation from chick aortic ring was quantified using image-
pro software.
Chick embryo chorioallantoic membranes (CAM)
models
5-Day-old fertilized chicken eggs were incubated at 37C
in 60% humidity for additional 48 h. On day 3, a small hole
in the shell concealing the air sac was made with a hypo-
dermic needle. By candling, a second hole was made on the
broad side of the egg directly over the avascular portion of
the embryonic membrane. A false air sac was created
beneath the second hole by applying negative pressure
through the first hole, causing the CAM to separate from
the shell. A window of about 1 cm2 was cut into the shell
over the dropped CAM using a small grinding wheel.
VEGF (20 ng/ml) was used as a standard proangiogenic
agent. Sterile disks of filter paper (Whatman International)
were pretreated with 3 mg/ml cortisone acetate and air
dried under sterile conditions. The disks were suspended in
PBS containing different concentrations of ellagic acid and
VEGF, and then placed on the growing CAMs. After
3 days, the tissue directly beneath each disk was reselected
from the control and the treated CAM samples. Each tissue
sample was washed three times with PBS and digital
images were collected. The images were then analyzed by
Image-J software. Six regions were randomly selected and
the number of vessel branch points contained in a circular
region was counted. The resulting angiogenesis index was
expressed as mean ± SD of the branch points for each
CAM sample. The experiments were repeated three times.
Xenograft models and immunohistochemistry
detections
Use of animal has been approved by the Committee on the
Use of Live Animal in the Teaching and Research of the
University of Hong Kong. 3 9 106 Human breast cancer
MDA-MB-231 cells were implanted into the mammary
glands of female, 4-week-old BALB/c nude mice to build
breast cancer xenograft. Mice with appropriate size of
tumors were divided randomly into three groups including
control group, ellagic acid low-dosage group (50 mg/kg/
day), and ellagic acid high-dosage group (100 mg/kg/day).
The mice were treated with ellagic daily by intraperitoneal
administration. Tumor volume and mice body weight were
measured every 3 days. Tumor volume was detected by
caliper measurements and determined by formula:
 * width2 * length. After sacrificing mice on day 25,
tumors and normal tissues will be harvested for molecular
assessment. Specifically, tumors and normal tissues were
fixed in 10% paraformaldehyde/PBS, dehydrated in 70%
ethanol, embedded in 4% paraffin at 4C, and then sec-
tioned (4 lm). Deparaffinized tumor sections were stained
with specific antibodies including CD31, P-VEGFR2,
P-AKT, and P-JNK (Cell Signaling) Detection was done
with avidin–biotin–HRP complex (Thermo scientific,
Fremont, CA) and diaminobenzidine as chromogen. Nuclei
were counterstained with hematoxylin. Besides, deparaffi-
nized normal tissue sections including heart, liver, spleen,
lung, and kidney will be stained with hematoxylin and
eosin (H&E) for toxicological analysis.
Molecular docking
The LigandFit algorithm in Discovery Studio 2.1 with the
CHARMm engine was applied in our molecular docking
study. Chemoffice2002 (CambridgeSoft, Cambridge, MA)
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were used for the drawing of chemical structures. The
LigandFit algorithm employed the strategy including initial
generation of ligand orientations within VEGFR-2 catalytic
domain followed by molecular dynamics (MD)-based
simulated annealing, and final refinement by energy mini-
mization. The crystal structure of VEGFR-2 was obtained
from Protein Data Bank (http://www.rcsb.org/pdb/) with
the PDB ID of 1Y6B. The water molecules in VEGFR-2
were removed. For the docking purpose, the ATP site
within VEGFR-2 was defined as the ligand-binding site
following the template of 1Y6B, and ellagic acid was
docked into VEGFR-2 with proper parameter setting.
Specifically, starting from the initial configuration, 100
different orientations of ellagic acid were randomly gen-
erated and docked into the ATP pocket of VEGFR-2. All
the 100 docking poses were presented simultaneously for
the analysis of the interactions between ellagic acid and
VEGFR-2. A docking without any output pose was con-
sidered as a failure.
Results
Ellagic acid inhibited proliferation of HUVECs induced
by VEGF
To examine the anti-angiogenic effects of ellagic acid in
vitro, proliferation of VEGF-induced HUVECs was
detected first [22]. Previous studies reported that cell
number decreased while MTT formazan formation
increased in the presence of polyphenol-associated com-
pound (kaempferol) [23]. Therefore, cell counting assay
was conducted rather than MTT assay in this study. As
shown in Fig. 1a, the proliferation of endothelial cells
stimulated by VEGF was markedly decreased after ellagic
acid treatment ranging from 2.5 to 20 lM. Besides,
HUVECs not containing VEGF showed obscure changes in
cell proliferation, indicating extracellular VEGF acted as a
strong attractant for endothelial cells proliferation. Then
we treated endothelial cells with ellagic acid at different
time intervals of 12, 24, and 48 h. The results presented in
Fig. 1b showed that ellagic acid significantly suppressed
endothelial cell proliferation in a time course. As detected
by BrdU incorporation assay (Fig. 1c), DNA synthesis of
HUVECs was also significantly inhibited by ellagic acid in
a dose-dependant manner. To validate whether or not
ellagic acid would result in toxicity effects on HUVECs,
LDH cytotoxicity assay was carried out. As shown in
Fig. 1d, ellagic acid brought little toxic effects on
HUVECs. Meanwhile, there were little abnormal mor-
phological changes of endothelial cells after ellagic acid
administration for 48 h (Fig. 1e). We came to the conclu-
sion that ellagic acid at non-cytotoxic doses could
significantly inhibit proliferation of VEGF-stimulated
endothelial cells.
Ellagic acid suppressed VEGF-induced migration
and tube formation of HUVECs
Then, we studied the potential of ellagic acid in blocking
the migration and tube formation abilities of HUVECs
[24]. First, transwell assay demonstrated that the invasive
cells to the lower chamber were significantly decreased
with the increasing concentration of ellagic acid (Fig. 2A),
indicating that the migration ability of HUVECs was dose
dependently suppressed by ellagic acid. Meanwhile, the
influence of ellagic acid on migration ability of endothelial
cells was also assessed by wound-healing assay. As shown
in Fig. 2B, the gap width of control group narrowed more
obviously than that of ellagic acid-treated group from 0 to
24 h, reflecting that ellagic acid could time dependently
weaken the migration capability of endothelial cells. Then
the effects of ellagic acid on tube-formation ability of
HUVECs were tested on Matrigel. In Fig. 2C, HUVECs
showed well-formed tubular structure in the absence of
ellagic acid. Capillaries were gradually abrogated due to
increasing ellagic acid concentrations. Almost 80%
destruction of tube network was observed when HUVECs
were incubated with ellagic acid at 10 lM. Taken together,
ellagic acid suppressed the migratory process and tube
formation activities of endothelial cells in the presence of
VEGF.
Ellagic acid blocked angiogenesis in chick-associated
models
To mimic the in vivo angiogenesis situation, the organo-
typic assay in chick aortic arch model was then conducted
by measurement of endothelial cell outgrowth [25]. It was
found that sprouts around ellagic acid-treated rings were
shorter and fewer cells migrated into the matrix, suggesting
that ellagic acid could inhibit the sprout length and density
after stimulation of VEGF (Fig. 3a). We further examined
whether the inhibitory effects of ellagic acid were revers-
ible. As shown in Fig. 3b, removal of ellagic acid con-
tributed to sprout recurrence around the aortic ring,
indicating that ellagic acid brought little toxic effects on
normal vessel tissues. Besides, a different chick model
system by in vivo chick embryonic CAM assay showed
that the number of blood vessels gradually decreased with
increasing concentrations of ellagic acid accompanied by
VEGF stimulation (Fig. 3c). Overall, it was demonstrated
that ellagic acid could inhibit sprouts formation from
chicken aorta model and microvessels formation in CAM
model.
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Ellagic acid attenuated VEGFR-2 tyrosine kinase
activity and VEGFR-2 signaling pathway
Previous studies indicated that blockage of VEGFR-2
activity could significantly limit tumoral neo-angiogenesis
process [26]. We first examined influences of ellagic acid
on tyrosine phosphorylation of VEGFR-2 (the active form
of VEGFR-2) stimulated by VEGF. The expression of
P-VEGFR2 (Tyr 1175) and total VEGFR-2 were assessed
by western blotting assay with their specific antibodies in
the presence of VEGF. As shown in Fig. 4a, there was a
significant reduction of P-VEGFR2 induced by ellagic
acid, while the total levels of VEGFR-2 had little changes.
We then investigated whether ellagic acid decreased
P-VEGFR2 levels by inhibiting the kinase activity of
VEGFR-2. Thus, ELISA-based tyrosine kinase assay was
conducted to further examine the effects of ellagic acid on
VEGF-stimulated P-VEGFR2. It was found that ellagic
acid could dose dependently suppress kinase activity of
VEGFR-2 with an IC50 of *25.8 nM (Fig. 4b). In
Fig. 1 Ellagic acid inhibited proliferation of HUVECs induced by
VEGF. a After the treatment with ellagic acid at different concen-
trations ranging from 2.5 to 20 lM for 48 h in the presence or
absence of VEGF, cell number was counted. The results showed that
the proliferation of HUVECs stimulated by VEGF was significantly
decreased in a dose-dependant manner, while ellagic acid had little
inhibitory effects on HUVECs that were not stimulated by VEGF
(values represent means ± SD, n = 6, *P \ 0.05, **P \ 0.01,
versus untreated control). b Time-course study indicated that ellagic
acid could markedly inhibit endothelial cell proliferation in a time-
dependant manner (values represent means ± SD, n = 6, *P \ 0.05,
**P \ 0.01, versus untreated control). c Effects of ellagic acid on
DNA synthesis were examined by BrdU cell proliferation enzyme-
linked immunosorbent assay. The results suggested that ellagic acid
could obviously inhibit DNA synthesis of HUVECs in a dose-
dependent manner (values represent means ± SD, n = 6, *P \ 0.05,
**P \ 0.01, versus untreated control). d The supernatants of
HUVECs after ellagic acid treatment were collected for cytotoxicity
examination by LDH cytotoxicity assay kit. The results showed that
ellagic acid administration did not result in LDH release from
endothelial cells, indicating that ellagic acid posed little cytotoxicity
effects upon HUVECs (values represent means ± SD, n = 6).
e VEGF-induced HUVECs were treated with ellagic acid at different
concentrations for 48 h, and then photographed by at 100-fold
magnification for the detection of HUVECs morphological changes.
Little abnormal morphological changes of HUVECs were observed
after 48-h exposure to ellagic acid. The results further demonstrated
that there was no significant toxicity of ellagic acid at any tested
concentration in the cellular level
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addition, previous studies supported that phosphorylation
of VEGFR-2 could subsequently trigger multiple down-
stream signals that induced proliferation and differentiation
activities of endothelial cells [27]. To better understand
inhibitory effects of ellagic acid on VEGFR-2 and its
downstream signaling, we next chose multiple essential
downstream signaling molecules involved in VEGFR-2
activation for western blotting detection. Results showed
that ellagic acid could evidently inhibit VEGF-stimulated
eNOS expression and phosphorylation levels of ERK,
AKT, and JNK, whereas the total expressions of the latter
three were almost unaffected. In addition, both the MMP-9
and MMP-2 activities were suppressed after ellagic acid
treatment (Fig. 4c). As ROS was also reported as a
downstream signaling after VEGFR-2 activation [28], we
also detect the ROS levels by DCFH-DA probe. The results
showed that the intracellular ROS level was significantly
reduced after ellagic acid administration (Fig. 4d). The
above results revealed that ellagic acid inhibited in vitro
angiogenesis by directly targeting VEGFR-2 on the surface
of endothelial cells, and further suppressing VEGFR2-
associated signaling pathways.
Fig. 2 Ellagic acid suppressed
VEGF-induced invasion,
migration, and tube formation
of HUVECs. a HUVECs at a
density of 2 9 105 cells/ml
were planted into a 6-well
transwell (8-lm pore size)
subsequently added with
different concentrations of
ellagic acid and VEGF. After
24 h incubation, the cells at the
bottom of the membrane were
fixed and analyzed. It was
showed that ellagic acid
decreased the number of
invasive cells in a dose-
dependent manner (a 0 lM,
b 2.5 lM, c 5 lM, d 10 lM;
data are presented as
means ± SD, n = 6, *P \ 0.05
versus untreated control). b A
total of 5 9 105 HUVECs per
well were seeded in a 6-well
plate for wound-healing assay.
The results showed that ellagic
acid significantly inhibit the
migration of HUVECs in the
presence of VEGF stimulation
(data are presented as
means ± SD, n = 6,
*P \ 0.05, **P \ 0.01 versus
untreated control). c HUVECs
were seeded at a density of
2 9 105 cells per well using a
12-well plate which was pre-
coated with Matrigel. Varying
concentrations of ellagic acid
(2.5, 5, and 10 lM) were added
together with VEGF (20 ng/ml)
for additional 8 h incubation. It
was observed that ellagic acid
could dose dependently
suppress the capillary lengths of
VEGF-stimulated endothelial
cells (a 0 lM, b 2.5 lM,
c 5 lM, d 10 lM; values
represent means ± SD, n = 6,
*P \ 0.05, **P \ 0.01 versus
untreated control)
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Ellagic acid inhibited breast cancer growth
and neoangiogenesis in vivo
To investigate in vivo anti-angiogenesis effects of ellagic
acid, breast cancer xenograft was built to evaluate whether
ellagic acid could suppress tumor-induced angiogenesis in
vivo. Previous studies indicated that MDA-MB-231 cell
line was the first choice as pre-clinical breast cancer model
owing to its high aggressive nature either in vitro or in vivo
[29]. Thus, immunodeficient mice bearing MDA-MB-231
xenografts were treated daily with or without ellagic acid
by intraperitoneal administration for 25 days. After mice
were sacrificed, tumors and tissues were taken out for
further analysis. Representative mice with MDA-MB-231
xenografts and tumor masses are shown in Fig. 5a. It was
found that treatment with ellagic acid significantly led to
suppression of MBA-MD-231 tumor volumes when com-
pared with the control group treated with vehicle, sug-
gesting that ellagic acid could inhibit tumor growth in vivo.
To further examine whether ellagic acid could suppress
breast cancer growth by inhibiting angiogenesis, tumor
tissues were stained with specific antibodies against CD31,
P-VEGFR2 (Tyr 1175), P-AKT, and P-JNK in Fig. 5b.
CD31 is a widely used endothelial marker for quantifying
angiogenesis by calculating microvessel density (MVD)
[30]. We found that vessels in vehicle-treated group were
more numerous and stained more intensely compared with
100 mg/kg ellagic acid-treated group. In addition, ellagic
acid treatment could obviously down-regulate expressions
of P-VEGFR2, P-Akt, and P-JNK, further demonstrating
Fig. 3 Ellagic acid blocked neo-angiogenesis in chick-associated
models. a Ellagic acid dose dependently suppressed sprout formation
on the organotypic model of chick aortic ring. Chick aortic rings were
embedded in Matrigel and treated with different concentrations of
ellagic acid stimulated by VEGF. The changes of sprout formations
around various aorta samples were observed on the 3rd day (left
panel; a 0 lM, b 2.5 lM, c 5 lM, d 10 lM). The index was defined
as a percentage of the untreated control (right panel, values are
represented as means ± SD, n = 6, *P \ 0.05, **P \ 0.01 versus
untreated control). b The inhibitory effects of ellagic acid on sprout
formation could be reversed after removal of ellagic acid from chick
aortic ring. Aortic ring was initially fed with both VEGF and ellagic
acid (10 lM) for 48 h (left panel), and then continually treated with
VEGF after removal of ellagic acid for an additional 48 h (right
panel). Images were representative of three independent experiments.
c Ellagic acid could inhibit the microvessels formation on in vivo
chick embryonic CAM model. Images were representative of three
independent experiments (left panel). The index was defined as the
mean number of visible microvessel branch with the defined area of
drug-containing pellets on each CAM model (right panel, values are
represented as means ± SD, n = 6, *P \ 0.05, **P \ 0.01 versus
untreated control)
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that ellagic acid played an important role in suppressing
angiogenesis at least partly through VEGFR-2 signaling
pathways.
Meanwhile, no significant differences of body weights
were detected among all the groups, indicating that ellagic
acid administration brought little toxic effects on mice.
Furthermore, normal tissue sections were embedded in
paraffin and stained by hematoxylin and eosin (H&E) for
toxicological analysis. No apparent pathological abnor-
malities were found in the normal tissues including heart,
liver, spleen, lung, and kidney. Therefore, we could draw
the conclusion that there were no significant adverse effects
of ellagic acid in vivo, and the inhibitory effects of ellagic
acid on cancer growth might not be due to systemic toxicity
in mice. The result in Fig. 5c could provide an experi-
mental basis for further study of ellagic acid in safe clinical
application.
Ellagic acid located at the ATP-binding sites
of VEGFR-2 kinase domain
We next analyzed the binding pattern between ellagic acid
and VEGFR-2 kinase domain to further understand how
ellagic acid exerted anti-angiogenesis effects via VEGFR-2
and its signaling pathways. The ATP site within VEGFR-2
kinase domain was thus defined as the ligand-binding site
Fig. 4 Ellagic acid attenuated VEGFR-2 tyrosine kinase activity and
VEGFR-2 signaling pathway. a Ellagic acid reduced the phosphor-
ylation of VEGFR-2 in VEGF-stimulated HUVECs. Endothelial cells
were pre-cultured with ellagic acid at different concentrations for
24 h with the stimulation of VEGF (20 ng/ml). Expressions of
VEGFR-2 and P-VEGFR2 were then examined by western blotting
assay. It was found that P-VEGFR2 expression was markedly
reduced, while the total level of VEGFR-2 was unaffected after the
treatment of ellagic acid. b Ellagic acid suppressed VEGFR-2 kinase
activity. VEGFR-2 and various concentrations of ellagic acid were
incubated in kinase reaction buffer in 96-well plate coated with a
poly-Glu-Tyr substrate. Phosphorylation of the substrate was moni-
tored with a purified phosphotyrosine specific monocolonal antibody
conjugated to horseradish peroxidase followed by chromogenic
reaction with horseradish peroxidase substrate. Data are presented
as a percentage of the control (values represent means ± SD, n = 3).
c Ellagic acid inhibited VEGFR-2 downstream signaling molecules,
including P-ERK/ERK, P-AKT/AKT, P-JNK/JNK, and e-NOS in a
dose-dependant manner. Besides, the expression of MMP-2 and
MMP-9 were also inhibited after ellagic acid administration. d The
HUVECs intracellular ROS level was detected by DCFH-DA staining
assay. The results showed that the intracellular ROS level was
significantly decreased after ellagic acid treatment (values represent
means ± SD, n = 6, *P \ 0.05, **P \ 0.01 versus untreated
control)
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based on the homology of 2-anilino-5-aryloxazole [31, 32].
As anticipated, ellagic acid could stably locate at the ATP-
binding pocket near the hinge region, which connected
N- and C-lobes within VEGFR-2 catalytic domain (Fig. 6).
Three active residues, i.e., Lys866, Glu883, and Phe1045 at
the ATP pocket were shown essential for the binding of
ellagic acid with VEGFR-2. Particularly, ellagic acid could
form hydrogen bonds with active residues Lys866 and
Glu883, which were located at the hinge region and played
an important role in identifying VEGFR-2 ligands. Besides,
ellagic acid could form strong p–p interactions with
Phe1045. The binding pattern of ellagic acid within
VEGFR-2 provided structural insight for development of
small natural inhibitors.
Fig. 5 Ellagic acid inhibited growth and neoangiogenesis on MDA-
MB-231 breast cancer xenografts. a Nude mice bearing MDA-MB-
231 tumor were treated daily with the vehicle or ellagic acid at 50 or
100 mg/kg/day by intraperitoneal administration for 25 days. Repre-
sentative mice with MDA-MB-231 xenografts and tumor masses were
shown. Besides, it was found that treatment with ellagic acid
obviously suppressed tumor volumes compared to the vehicle control
group, indicating that ellagic acid could significantly inhibit the
MBA-MD-231 tumor growth in vivo (values represent means ± SD,
n = 6, *P \ 0.05 versus vehicle group). b Tumor tissues were
prepared for immunohistochemistry detection with specific antibodies
against CD31, P-VEGFR2, P-AKT, and P-JNK. It was found that
ellagic acid could obviously decrease tumoral microvessel density
(MVD) indexed by CD31 in comparison with vehicle treatment.
Meanwhile, ellagic acid treatment could obviously attenuate expres-
sions of P-VEGFR2, P-Akt, and P-JNK, further demonstrating that
ellagic acid played an important role in suppressing angiogenesis at
least in part via VEGFR-2 signaling pathways in vivo. c Ellagic acid
resulted in little toxicity effects in vivo. No significant differences of
body weights were detected among all the groups (upper panel).
Besides, it was found that ellagic acid did not cause apparent
pathological abnormalities in the normal tissues including heart, lung,
liver, spleen, and kidney, suggesting that there were no significant
adverse effects of ellagic acid in vivo (down panel)
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Discussion
Extensive laboratory evidences supported that angiogenesis
can be detected throughout the onset, growth, and metas-
tasis in breast cancer [33]. Developing nontoxic anti-
angiogenesis agents has thus become a promising strategy
in breast cancer prevention and treatment. Ellagic acid is a
dietary-derived polyphenol which has been widely reported
to possess anti-cancer properties. In this study, we first
focused on the inhibitory effects of ellagic acid on several
steps of angiogenesis at the cellular level. It was found that
ellagic acid could markedly inhibit angiogenesis-associated
activities including proliferation, migration/invasion, and
capillary formation on VEGF-stimulated endothelial cells.
Besides, previous studies indicated that angiogenesis in
vivo involved not only endothelial cells but also their
surrounding cells [25]. Thus, chick aortic arch model was
then used to mimic the in vivo process of angiogenesis. As
anticipated, the sprouts formation stimulated by VEGF
from ellagic acid-treated aorta was weak and scattered
compared with the vehicle-treated groups. Nevertheless,
the above in-vitro models lack the biological complexity of
vascular system in vertebrate animals. Supporting evi-
dences concerning in vivo anti-angiogenesis effects of
ellagic acid then came from chick embryonic CAM model
and MDA-MB-231 tumor xenograft model. Ellagic acid
obviously inhibited blood vessels formation on CAM
model and significantly suppressed tumor growth accom-
panied by a reduced MVD on tumor tissues in MDA-
MB-231 xenograft model. Notably, we found that ellagic
acid did not pose significant cytotoxicity to HUVECs at any
tested concentrations based on LDH assay, indicating that
the inhibitory effects of ellagic acid was not likely due to
toxicity at the cellular level. In addition, vascular recurrence
after ellagic acid removal on CAM models and no obvious
toxic pathologic changes in normal tissues of mice xenograft
model further demonstrated that ellagic acid could exert
anti-angiogenesis effects with limited toxicity. These evi-
dences might provide an experimental basis for further study
of ellagic acid in safe clinical application.
We then verified the intrinsic mechanisms for the above
anti-angiogenesis activities of ellagic acid. Inhibition of
VEGFR-2 has been served as a prosperous strategy for
angiogenesis therapeutic intervention [34]. By functionally
coupling with VEGF, VEGFR-2 would undergo auto-
phosphorylation mainly at Tyr1175 sites within its intra-
cellular kinase domain and then initiate a series of
downstream signal transductions to endothelial cells [35].
Our findings revealed that ellagic acid could suppress
Tyr1175 phosphorylation of VEGFR-2 stimulated by
VEGF as well as VEGFR-2 tyrosine kinase activity. Mul-
tiple VEGFR-2 downstream signaling mediators such as
ERK, AKT, JNK, and eNOS were also involved in regu-
lation of endothelial cells survival and proliferation.
According to previous supporting evidences [36, 37], P42/
44 ERK activation attributes to an increased proliferation
on endothelial cells; AKT is responsible for the survival of
endothelial cell; JNK activation induces proliferation and
migration on endothelial cells by promoting nuclear acti-
vation of c-Jun; and eNOS plays a key role in vascular
permeability and migration activities on endothelial cells.
Our results demonstrated that multiple MAPK signaling
mediators including p-ERK, p-AKT, p-JNK, and eNOS
were inhibited by ellagic acid. In addition, it was also
found that ellagic acid dose dependently inhibited MMPs
activity, confirming the previous findings that decreased
MMPs activity might be also responsible for interfering
with the binding of VEGF to VEGFR-2, and therefore
inhibiting the neo-angiogenesis process [38]. Furthermore,
ROS was reported as a downstream signaling of VEGFR-2
and served as a survival mediator in supporting endothelial
cells proliferation [28]. Our results showed that the ROS
level was significantly decreased after ellagic acid admin-
istration, which might be a consequence event of decreased
VEGFR-2 activity. All these results showed that ellagic
acid treatment suppressed the VEGFR-2 pathways. Mean-
while, the findings in vitro were also consistent with our in
vivo results, indicating that the reduced MVD value may
owe to the suppression activities of ellagic acid on the
expression of phosphorylated VEGFR-2 and its down-
stream signaling molecules.
To thoroughly understand how ellagic acid interacted
with VEGFR-2 to exert anti-angiogenesis effects, we fur-
ther examined the structure-based interaction between
Fig. 6 Ellagic acid interacted with the ATP-binding sites of VEGFR-
2 kinase domain. The LigandFit algorithm in Discovery Studio 2.1
was applied to predict the binding mode of ellagic acid within ATP-
binding domain of VEGFR-2 kinase. As anticipated, ellagic acid
could stably bind to the ATP-binding pocket near the hinge region,
which connected N- and C-lobes within VEGFR-2 catalytic domain.
Specifically, ellagic acid formed hydrogen bonds with residues
Lys866 and Glu883. Besides, ellagic acid could form strong p–p
interactions with Phe1045
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ellagic acid and VEGFR-2 in silico. The identification of
VEGF with VEGFR-2 is tightly associated with the second/
third immunoglobulin-like regions within the VEGFR-2
extracellular domain. Besides, the downstream structure
from the fourth to seventh immunoglobulin-like domains in
VEGFR-2 plays a major role in dimerization and activation
[39]. Disappointedly, it has been shown that the overall
structure of VEGFR-2 extracellular domain is excessively
flexible and change too much before and after binding with
VEGF. Therefore, this dynamic nature prevented extra-
cellular domain to be a good target for small molecular
inhibitors.
As mentioned above, dimerization within the extracel-
lular domain of VEGFR-2 could induce the autophospho-
rylation on numerous tyrosine residues within its
intracellular domain. The phosphorylation is an ATP-
consuming process. The ATP-binding region lies between
N-terminal lobe and C-terminal lobe within VEGFR-2
catalytic domain. Many kinase inhibitors could exert their
inhibitory effects through purely or partially competing
against the adenosine triphosphate (ATP) and subsequently
suppressing the receptor autophosphorylation. They were
acting as ATP minetics that bound to this site and com-
peted with cellular ATP [9, 11–13]. In this study, ellagic
acid could stably locate at the ATP-binding pocket near the
hinge region. At least 16 active residues existed within the
catalytic unit of VEGFR-2, including Val846, Phe1045,
Cys1043, Leu1033, Asn1031, Arg1030, Asn921, Gly920,
Lys918, Cys917, Phe916, Val914, Lys866, Ala864,
Gly841, Glu883, and Leu838. Only three active residues,
i.e., Lys866, Glu883, and Phe1045 at the ATP pocket were
essential for the stable conformation of VEGFR-2/ellagic
acid complex. The binding mode of ellagic acid with
VEGFR-2 differed considerably from that of 2-anilio-5-
aryoxazole (1Y6B) [31], although they shared similar
aromatic interaction with the same residue Phe1045. In
addition to the strong p–p interactions with Phe1045,
ellagic acid could also form hydrogen bonds mainly with
two residues, i.e., Glu883 and Lys866. All the unique
binding modes largely promoted the conformational sta-
bility of the ellagic acid/VEGFR-2 complex.
Overall, our study indicated that ellagic acid at non-
toxic dosages exerted potent anti-angiogenesis activities
via specifically targeting VEGFR-2 and its signaling
pathway in breast cancer. As a natural inhibitor against
VEGFR-2 with limited toxicity, ellagic acid is a prom-
ising candidate for development of anti-angiogenesis
agents.
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